{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:09:59Z","timestamp":1790392199664,"version":"4.1.0"},"reference-count":38,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031584","name":"German Center for Diabetes Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031584","name":"DZD","doi-asserted-by":"publisher","award":["82DZD09D03"],"award-info":[{"award-number":["82DZD09D03"]}],"id":[{"id":"10.13039\/100031584","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Obesity is a key driver of metabolic dysfunction-associated steatotic liver disease. Beyond lifestyle modification, pharmacological and surgical therapies were recently established. This study compared the effects of lifestyle therapy, lifestyle plus semaglutide, and bariatric surgery on noninvasive markers of hepatic steatosis and fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this single-center, prospective, observational cohort study, 92 adults with obesity were analyzed over 72 weeks. Patients received (1) lifestyle-based multimodal therapy ([LIFESTYLE], n = 30), (2) lifestyle plus semaglutide therapy ([SEMA], n = 30, semaglutide 1.0 \u00b1 0.4\u2005mg\/week), or (3) lifestyle plus laparoscopic sleeve gastrectomy (LSG) ([SURGERY], n = 32). Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were assessed using FibroScan\u00ae; Fibrosis-4 and FibroScan-AST scores were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, all patients showed hepatic steatosis. Over 72 weeks, CAP decreased significantly (P &amp;lt; .001) with a reduction of \u221217.9 \u00b1 14.0 (LIFESTYLE), \u221246.0 \u00b1 14.0 (SEMA), and \u221283.7 \u00b1 10.0\u2005dB\/m (SURGERY), respectively (overall P = .002). Baseline LSM differed between groups and declined by \u22120.8 \u00b1 1.0, \u22122.8\u00b1\u202f0.8, and \u22124.9 \u00b1 1.1\u2005kPa, respectively (overall P &amp;lt; .001), without significant differences between SEMA and SURGERY in relative reduction (P = .428). FibroScan-AST scores decreased significantly over time across all groups (P &amp;lt; .001). Fibrosis-4 increased modestly after SURGERY (+0.29; P &amp;lt; .001) while remaining stable in SEMA and LIFESTYLE (both P &amp;gt; .3). Weight loss amounted to \u22124.2 \u00b1 1.8, \u221210.7 \u00b1 1.5, and \u221231.6 \u00b1 1.5%. Liver stiffness measurement improvement was weight dependent in SURGERY (P = .027), while LSM improvement in SEMA occurred independently of weight change (P = .508).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Semaglutide and LSG both improved noninvasive markers for hepatic steatosis and fibrosis, whereas lifestyle intervention alone showed limited benefit. Despite differing degrees of weight loss, adjusted liver stiffness did not differ significantly between semaglutide and surgery, a hypothesis-generating finding that warrants further investigation into weight-independent mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag350","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:41:36Z","timestamp":1787830896000},"source":"Crossref","is-referenced-by-count":1,"title":["Effects of semaglutide vs bariatric surgery on noninvasive markers of hepatic steatosis and fibrosis in obesity with metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5646-9537","authenticated-orcid":false,"given":"Paula","family":"L\u00fcnswilken","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 1, Endocrinology & Diabetes, UKSH , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"Center of Brain, Behavior and Metabolism, University of Luebeck , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"German Center for Diabetes Research (DZD) , 85764 Munich-Neuherberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Worobiec","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Endocrinology & Diabetes, UKSH , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"Center of Brain, Behavior and Metabolism, University of Luebeck , 23562 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9092-2822","authenticated-orcid":false,"given":"Lara S","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Endocrinology & Diabetes, UKSH , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"Center of Brain, Behavior and Metabolism, University of Luebeck , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"German Center for Diabetes Research (DZD) , 85764 Munich-Neuherberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7675-4740","authenticated-orcid":false,"given":"Julia","family":"Altrogge","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Endocrinology & Diabetes, UKSH , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"Center of Brain, Behavior and Metabolism, University of Luebeck , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"German Center for Diabetes Research (DZD) , 85764 Munich-Neuherberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schenk","sequence":"additional","affiliation":[{"name":"Department of Surgery, UKSH , 23562 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Jegodzinski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Endocrinology & Diabetes, UKSH , 23562 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Wilms","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Endocrinology & Diabetes, UKSH , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"Center of Brain, Behavior and Metabolism, University of Luebeck , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"German Center for Diabetes Research (DZD) , 85764 Munich-Neuherberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens U","family":"Marquardt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Endocrinology & Diabetes, UKSH , 23562 L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-7022","authenticated-orcid":false,"given":"Svenja","family":"Meyh\u00f6fer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Endocrinology & Diabetes, UKSH , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"Center of Brain, Behavior and Metabolism, University of Luebeck , 23562 L\u00fcbeck ,","place":["Germany"]},{"name":"German Center for Diabetes Research (DZD) , 85764 Munich-Neuherberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"1","key":"2026092511112542000_dgag350-B1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"2026092511112542000_dgag350-B2","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1038\/s41467-024-48956-0","article-title":"Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD","volume":"15","author":"Verschuren","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"2026092511112542000_dgag350-B3","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"1","key":"2026092511112542000_dgag350-B4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"2026092511112542000_dgag350-B5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"2026092511112542000_dgag350-B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155937","article-title":"Obesity and MASLD: is weight loss the (only) key to treat metabolic liver disease?","volume":"157","author":"Huttasch","year":"2024","journal-title":"Metabolism"},{"issue":"3","key":"2026092511112542000_dgag350-B7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cgh.2021.03.017","article-title":"Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"20","author":"Jirapinyo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"2026092511112542000_dgag350-B8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"2026092511112542000_dgag350-B9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"2026092511112542000_dgag350-B10","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J Hepatol"},{"key":"2026092511112542000_dgag350-B11","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"key":"2026092511112542000_dgag350-B12","author":"Klein"},{"issue":"1","key":"2026092511112542000_dgag350-B13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"issue":"5","key":"2026092511112542000_dgag350-B14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.dld.2007.10.019","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD)","volume":"40","author":"Yoneda","year":"2008","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2026092511112542000_dgag350-B15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0016-5085(00)70364-7","article-title":"Liver fibrosis in overweight patients","volume":"118","author":"Ratziu","year":"2000","journal-title":"Gastroenterology"},{"issue":"4","key":"2026092511112542000_dgag350-B16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cgh.2022.05.015","article-title":"Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients","volume":"21","author":"Ito","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10S","key":"2026092511112542000_dgag350-B17","doi-asserted-by":"crossref","first-page":"S1379","DOI":"10.14309\/01.ajg.0001037068.07637.b1","article-title":"S1925 limitations of FIB-4 score in excluding advanced fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"119","author":"Bentley","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"2026092511112542000_dgag350-B18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/gutjnl-2022-328689","article-title":"Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis","volume":"72","author":"Ravaioli","year":"2023","journal-title":"Gut"},{"issue":"4","key":"2026092511112542000_dgag350-B19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026092511112542000_dgag350-B20","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"2026092511112542000_dgag350-B21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study","volume":"55","author":"Foucher","year":"2006","journal-title":"Gut"},{"issue":"12","key":"2026092511112542000_dgag350-B22","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"issue":"9","key":"2026092511112542000_dgag350-B23","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/gut.2007.126417","article-title":"Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"56","author":"Yoneda","year":"2007","journal-title":"Gut"},{"issue":"3","key":"2026092511112542000_dgag350-B24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"2026092511112542000_dgag350-B25","author":"Deutsche Adipositas-Gesellschaft (DAG) e.V"},{"key":"2026092511112542000_dgag350-B26"},{"issue":"4","key":"2026092511112542000_dgag350-B27","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2026092511112542000_dgag350-B28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"2026092511112542000_dgag350-B29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev"},{"issue":"2","key":"2026092511112542000_dgag350-B30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"2026092511112542000_dgag350-B31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/oby.24331","article-title":"Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity"},{"issue":"10","key":"2026092511112542000_dgag350-B32","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.2337\/dc24-1082","article-title":"Real-world use of semaglutide for weight management: patient characteristics and dose titration\u2014a Danish Cohort Study","volume":"47","author":"Ladebo","year":"2024","journal-title":"Diabetes Care"},{"issue":"3","key":"2026092511112542000_dgag350-B33","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"11","key":"2026092511112542000_dgag350-B34","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","article-title":"Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population","volume":"20","author":"Graupera","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2026092511112542000_dgag350-B35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"2026092511112542000_dgag350-B36","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.cmet.2026.03.011","article-title":"The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors","volume":"38","author":"Gonzalez-Rellan","year":"2026","journal-title":"Cell Metab"},{"issue":"4","key":"2026092511112542000_dgag350-B37","doi-asserted-by":"crossref","first-page":"O1","DOI":"10.1002\/oby.22719","article-title":"Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures\u20142019 update","volume":"28","author":"Mechanick","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"2026092511112542000_dgag350-B38","doi-asserted-by":"crossref","unstructured":"L\u00fcnswilken P, Worobiec K, Braun LS, et al \u00a0Data from: Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD. Figshare. 2026. doi:10.6084\/m9.figshare.33306696.","DOI":"10.1210\/clinem\/dgag350"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag350\/70818330\/dgag350.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag350\/70818330\/dgag350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:11:38Z","timestamp":1790349098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag350\/8771726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":38,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag350","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"dgag350"}}